On January 22nd the Chris Elliott Fund joined forces with Foundation Medicine for a dinner at Cuoco in the South Lake Union neighborhood of Seattle.
We came together to discuss the future of cancer research and the impact of genomic profiling and DNA sequencing on its future, especially for brain cancer and brain tumor patients. We are excited about the future of Foundation Medicine and their comprehensive genomic profiling test Foundation One, as it shows promise in shifting the paradigm around genetic testing for cancer patients, especially for brain cancer patients.
We were pleased to set up an evening among our Seattle peers to meet, chat and hear a presentation from Foundation Medicine’s Director of Medical Affairs Dr. Gary Palmer.
Attendees from the event included neurologists from Swedish Medical Center and the University of Washington. Also local representatives from organizations influencing the future of brain cancer treatment included individuals from Novocure (providing the NovoTTF device) and Arbor Pharmaceuticals (who provide the Gliadel Wafer). Also Cancer Treatment Navigator Hartmut Stecher was present as well as many friends, caregivers, and advocates of the Chris Elliott Fund.
We are looking forward to providing more Dinner & Learn events in the coming months, including another one with Foundation Medicine. Registration is not yet open for future dinner & learn events, but let us know you’re interested by leaving us a note on our contact us page.